Public market insider buying at ESSA Pharma (EPI)

Public market insider buying at ESSA Pharma (V:EPI)

Franklin Milan Berger, a Director, acquired 229,565 Common Shares on a direct ownership basis at prices ranging from US$5.370 to US$5.400 between February 19th and 20th, 2020. This represents a $1,634,152 investment into the company's shares and an account share holdings change of greater than 100%.

ESSA Pharma is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

ESSA Pharma, Inc. is a Canada-based pharmaceutical company. The Company is focused on developing therapies for the treatment of castration-resistant prostate cancer (CRPC). It is developing EPI-7386 for the treatment of metastatic CRPC (mCRPC). It is also developing EPI-7386 combination therapy for mCRPC. Its pipeline also includes antinen for triple negative androgen receptor (AR+) breast cancer. Its proprietary aniten compounds bind to the N-terminal domain of the androgen receptor (AR), inhibiting ARdriven transcription and the AR signaling pathway in a manner which bypasses the drug resistance mechanisms associated with current anti-androgens. ESSA Pharma Inc. (EPI) has a high amount of executive buying compared to its small-cap peers in the market over the past three months. According to regulatory filings yesterday, one insider has invested a total amount of $1,634,152.